Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus

Antiviral Research

Volumn 59, Issue 3, 2003, Pages 155-161

  Julander, Justin G ^a   Colonno, Richard J ^b   Sidwell, Robert W ^a   Morrey, John D ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Entecavir; HBV; Hepatitis B virus; Transgenic mouse

Indexed keywords

ENTECAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EVALUATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TITRIMETRY; TRANSGENIC MOUSE; VIRUS EXPRESSION;

ANIMALIA; HEPATITIS B VIRUS; MUS MUSCULUS;

EID: 0042632899     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00109-8     Document Type: Article

References (19)

1. Billich A. Entecavir (Bristol-Myers Squibb). Curr. Opin. Investig. Drugs. 2:2001;617-621.
2. Budelier, K., Schorr, J., 1995. Preparation and analysis of DNA. In: Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smih, J.A., Struhl, K. (Eds.), Current Protocols in Molecular Biology. Wiley, USA, pp. 2.9.7-2.9.8.
3. Cavanaugh V.J., Guidotti L.G., Chisari F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71:1997;3236-3243.
4. Chang, T.T., Hadziannis, S., Cianciara, J., Rizetto, M., Schiff, E., Pastore, G., Klesczewski, K., Denisky, G., Hindes, R., 2002. Sustained Viral Load and ALT Who Failed Lamivudine. AASLD, Boston.
5. Colonno R.J., Genovesi E.V., Medina I., Lamb L., Durham S.K., Huang M.L., Corey L., Littlejohn M., Locarnini S., Tennant B.C., Rose B., Clark J.M. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. 184:2001;1236-1245.
6. de Man R.A., Wolters L.M., Nevens F., Chua D., Sherman M., Lai C.L., Gadano A., Lee Y., Mazzotta F., Thomas N., DeHertogh D. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 34:2001;578-582.
7. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep. 50:1996;219-244.
8. Genovesi E.V., Lamb L., Medina I., Taylor D., Seifer M., Innaimo S., Colonno R.J., Standring D.N., Clark J.M. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42:1998;3209-3217.
9. Guidotti L.G., Matzke B., Schaller H., Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69:1995;6158-6169.
10. Innaimo S.F., Seifer M., Bisacchi G.S., Standring D.N., Zahler R., Colonno R.J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:1997;1444-1448.
11. Julander J.G., Sidwell R.W., Morrey J.D. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antivir. Res. 55:2002;27-40.
12. Kajino K., Kamiya N., Yayasa S., Takahara T., Sakurai J., Yamamura K.-I., Hino O. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy. Biochem. Biophys. Res. Commun. 241:1997;43-48.
13. Lai C., Rosmawati M., Lao J., Vlierberghe H., Anderson F., Thomas N., DeHertogh D. A phase II study of entecavir vs. lamivudine in adults with chronic hepatitis B. J. Hepatol. 34:2001;24.
14. Levine S., Hernandez D., Yamanaka G., Zhang S., Rose R., Weinheimer S., Colonno R.J. Efficacies of entecavir against lamivudine-resistant hepatitis b virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46:2002;2525-2532.
15. Marion P.L., Salazar F.H., Winters M.A., Colonno R.J. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. 46:2002;82-88.
16. Morrey, J.D., Sidwell, R.W., Korba, B.A., 1999. Animal models for HBV infections - transgenic mice. In: Zak, O., Sande, M. (Eds.), Handbook of Animal Models of Infection. Academic Press, London, pp. 1009-1019.
17. Raney A.K., Eggers C.M., Kline E.F., Guidotti L.G., Pontoglio M., Yaniv M., McLachlan A. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J. Virol. 75:2001;2900-2911.
18. Seifer M., Hamatake R.K., Colonno R.J., Standring D.N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42:1998;3200-3208.
19. Yamanaka G., Wilson T., Innaimo S., Bisacchi G.S., Egli P., Rinehart J.K., Zahler R., Colonno R.J. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. 43:1999;190-193.